Plasma-derived product · developed by Kamada
Kamada AAT is an inhaled formulation of alpha-1 antitrypsin, the protein that is deficient in alpha-1 antitrypsin deficiency. It is being studied for emphysema and alpha-1 antitrypsin deficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01217671 | Phase 2/3 | Emphysema | Completed | KMDA |
| NCT02001688 | Phase 2 | Alpha-1 Antitrypsin Deficiency | Completed | KMDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha-1 Antitrypsin DeficiencyEmphysema
See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KMDA catalysts and pipeline →